Luye Pharma Group’s Subsidiary Boan Biotechnology Reports 18.4% Revenue Growth in H1 2023
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...
Luye Pharma
Luye Pharma Group Submits Market Approval Filing for Lurbinectedin in Metastatic SCLC in Macau
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing has been...
Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug
China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...
Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance
Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has...
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA
China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...
Luye Pharma’s Boan Biotechnology Partners with GenScript on GenCircle dsDNA Development
Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186),...
Luye Pharma’s Bevacizumab Biosimilar Accepted for Review in Brazil by ANVISA
China-based Luye Pharma Group (HKG: 2186) has announced that the market approval filing for its...
Luye Pharma Group Partners with Duopharma for Exclusive Marketing Rights of TCM in Malaysia
China-based Luye Pharma Group (HKG: 2186) has signed an agreement with Malaysia’s Duopharma Marketing Sdn...
Luye Pharma Group Reports 15% Revenue Growth in 2022 Financial Results
China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total...
Luye Pharma’s Lurbinectedin Gains Priority Review Status for SCLC Treatment
The Center for Drug Evaluation (CDE) website indicates that China-based Luye Pharma Group’s (HKG: 2186)...
Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...
Luye Pharma’s Biosimilar BA9101 Completes Phase III Study Enrollment with Ocumension
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has completed...
Luye Pharma’s Paliperidone Palmitate Approved for European Clinical Trials
China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval in Europe for...
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
Luye Pharma Gains CDE Approval for Goserelin Acetate Microspheres Clinical Study
China-based Luye Pharma Group (HKG: 2186) has announced receiving approval from the Center for Drug...
Luye Pharma’s Rykindo Receives FDA Approval for Schizophrenia and Bipolar I Disorder
China-based Luye Pharma Group (HKG: 2186) has announced receiving market approval from the US Food...
Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong
China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program...
Luye Pharma’s BA1301 Receives CDE Approval for Clinical Trials
China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval from the Center...